Orally disintegrating tablets containing famotidine nanoparticles provide high intestinal absorbability
endocytosis
famotidine
freeze-drying
intestinal absorption
nanoparticle
orally disintegrating tablet
Journal
Frontiers in bioengineering and biotechnology
ISSN: 2296-4185
Titre abrégé: Front Bioeng Biotechnol
Pays: Switzerland
ID NLM: 101632513
Informations de publication
Date de publication:
2023
2023
Historique:
received:
16
02
2023
accepted:
01
03
2023
entrez:
27
3
2023
pubmed:
28
3
2023
medline:
28
3
2023
Statut:
epublish
Résumé
The permeability of the Biopharmaceutics Classification System (BCS) class III drugs are low, and their oral bioavailability needs to be improved. In this study, we attempted to design oral formulations containing famotidine (FAM) nanoparticles to overcome the limitations of BCS class III drugs. Dispersions containing FAM nanoparticles with a particle size of approximately 50-220 nm were produced by the bead-milling treatment. Moreover, we succeeded in preparing an orally disintegrating tablet containing FAM nanoparticles using the dispersions described above, additives (D-mannitol, polyvinylpyrrolidone, and gum arabic), and freeze-dry treatment (FAM-NP tablet). The FAM-NP tablet was disaggregated 3.5 s after addition to purified water, and the FAM particles in the redispersion of the FAM-NP tablet stored for 3 months were nano-sized (141 ± 6.6 nm). The
Identifiants
pubmed: 36970629
doi: 10.3389/fbioe.2023.1167291
pii: 1167291
pmc: PMC10036753
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1167291Informations de copyright
Copyright © 2023 Nagai, Ogata, Kadowaki, Deguchi, Otake, Nakazawa, Nagata, Sasaki and Kawasaki.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Nanomedicine. 2019 Feb 18;14:1213-1227
pubmed: 30863055
Int J Pharm. 2014 Nov 20;475(1-2):496-503
pubmed: 25219321
Toxicology. 2014 May 7;319:53-62
pubmed: 24598350
Biochim Biophys Acta. 2012 Mar;1818(3):502-11
pubmed: 22155257
J Pharm Sci. 2017 Jan;106(1):39-65
pubmed: 27816266
Int J Nanomedicine. 2019 Oct 01;14:7921-7931
pubmed: 31632009
Pharmaceutics. 2021 Sep 03;13(9):
pubmed: 34575479
Best Pract Res Clin Gastroenterol. 2001 Jun;15(3):355-70
pubmed: 11403532
Drug Deliv. 2020 Dec;27(1):110-127
pubmed: 31885288
Lancet. 2009 Oct 24;374(9699):1449-61
pubmed: 19683340
Pharmacol Rev. 2013 Jan;65(1):315-499
pubmed: 23383426
Dokl Biol Sci. 2014 Nov;459:330-3
pubmed: 25560208
AAPS PharmSciTech. 2017 Nov;18(8):3064-3075
pubmed: 28516414
Pharmaceutics. 2020 Apr 01;12(4):
pubmed: 32244754
Pharmaceutics. 2022 Feb 10;14(2):
pubmed: 35214118
Adv Drug Deliv Rev. 2006 Dec 30;58(15):1688-713
pubmed: 17118485
Sci Rep. 2018 Mar 28;8(1):5298
pubmed: 29593309
Int J Pharm. 2010 Sep 15;397(1-2):1-8
pubmed: 20600734
J Control Release. 2014 Oct 28;192:95-102
pubmed: 25009979
Int J Pharm. 2014 May 15;466(1-2):223-32
pubmed: 24614581
Eur J Pharm Biopharm. 2008 Aug;69(3):993-1003
pubmed: 18396390
Int J Nanomedicine. 2021 Aug 10;16:5343-5356
pubmed: 34413642
Int Sch Res Notices. 2014 Dec 07;2014:452051
pubmed: 27379272
Am J Med. 1986 Oct 24;81(4B):33-41
pubmed: 2877573
Mol Ther. 2009 Aug;17(8):1411-7
pubmed: 19532143
J Pharm Pharmacol. 2010 Nov;62(11):1622-36
pubmed: 21039546